TY - JOUR
T1 - Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer
AU - Timmer-Bonte, J.N.H.
AU - Punta, C.J.A.
AU - van der Heijden, H.F.M.
AU - van Die, C.E.
AU - Bussink, J.
AU - Beijnen, J.H.
AU - Huitema, A.D.R.
AU - Tjan-Heijnen, V.C.G.
N1 - ISI:000256749800010
PY - 2008
Y1 - 2008
N2 - In advanced non-small cell. tung cancer (NSCLC) the clinical benefit of a platinum-based doublet is only modest, therefore, attenuated dosed three-drug combinations are investigated. We hypothesized that with adequate support a full dosed chemotherapy triplet is feasible. The study was designed as a dose finding study of paclitaxel. in chemotherapy-naive patients. Paclitaxel. was given as a 3-h infusion on day 1, followed by fixed doses of teniposide (or etoposide) 100 mg/m(2) days 1, 3, 5 and cisplatin 80 mg/ml day 1 every 3 weeks. As myelotoxicity was expected to be the dose-limiting toxicity, prophylactic G-CSF and antibiotic support was evaluated. Indeed, paclitaxel. 120 mg/m(2) resulted in dose-limiting neutropenia, despite G-CSF support. teniposide/etoposide day 1, 3, 5 was less myelotoxic compared to day 1, 2, 3. G-CSF support allowed paclitaxel. dose-escalation to 250mg/m(2). The addition of prophylactic antibiotics enabled dose-escalation to 275mg/m(2) without reaching MTD. In conclusion, G-CSF and antibiotics prophylaxis enables the delivery of a full dosed chemotherapy triplet in previously untreated NSCLC patients. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
AB - In advanced non-small cell. tung cancer (NSCLC) the clinical benefit of a platinum-based doublet is only modest, therefore, attenuated dosed three-drug combinations are investigated. We hypothesized that with adequate support a full dosed chemotherapy triplet is feasible. The study was designed as a dose finding study of paclitaxel. in chemotherapy-naive patients. Paclitaxel. was given as a 3-h infusion on day 1, followed by fixed doses of teniposide (or etoposide) 100 mg/m(2) days 1, 3, 5 and cisplatin 80 mg/ml day 1 every 3 weeks. As myelotoxicity was expected to be the dose-limiting toxicity, prophylactic G-CSF and antibiotic support was evaluated. Indeed, paclitaxel. 120 mg/m(2) resulted in dose-limiting neutropenia, despite G-CSF support. teniposide/etoposide day 1, 3, 5 was less myelotoxic compared to day 1, 2, 3. G-CSF support allowed paclitaxel. dose-escalation to 250mg/m(2). The addition of prophylactic antibiotics enabled dose-escalation to 275mg/m(2) without reaching MTD. In conclusion, G-CSF and antibiotics prophylaxis enables the delivery of a full dosed chemotherapy triplet in previously untreated NSCLC patients. (C) 2007 Elsevier Ireland Ltd. All rights reserved.
M3 - Article
SN - 0169-5002
VL - 60
SP - 222
EP - 230
JO - Lung Cancer
JF - Lung Cancer
IS - 2
ER -
